Sr. Manager, Medical Information & Training

Zealand Pharma U.S., Inc.; Cambridge (MA); Hybrid; USD 120,000 - 180,000; Full time

Job summary

Zealand Pharma U.S., Inc. is seeking a Sr Manager, Medical Information & Training to own Medical Information responses and to lead Training & Resource development for the US Medical Affairs team.

The role spans obesity, amylin biology, and the petrelintide pipeline, supporting a growing US presence. The position emphasizes building foundational processes, onboarding and upskilling colleagues, and ensuring content is scientifically accurate and compliant through MLR review.

Qualifications

• PharmD required.
• Experience in medical information and/or medical communications within pharma or biotech.
• Experience designing and delivering training programs (adult learning and assessment methodology).
• Strong understanding of MLR review processes and compliance in medical communications.

Responsibilities

• Answer unsolicited HCP and patient inquiries with scientifically sound, timely responses.
• Author and update standard response documents.
• Ensure scientific accuracy and compliant content through MLR review.

Skills

Medical information

Medical communications

Training design

Adult learning

MLR compliance

Cross-functional collaboration

Scientific writing

Education

PharmD

Job description

Does it excite you to shape how a growing Medical Affairs organization answers scientific questions, builds knowledge, and trains its team, and do you have a PharmD and a passion for obesity and metabolic health? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague. Your new position As Sr Manager, Medical Information & Training, you will own two connected areas of impact: serving as our Medical Information Manager, responsible for answering unsolicited HCP and patient inquiries and ensuring scientifically accurate, compliant content, while also serving as our team's Training & Resource Lead, onboarding and upskilling our Medical Affairs team. This is a unique opportunity to build foundational processes and knowledge resources as we scale our US presence, working across obesity, amylin biology, and our petrelintide pipeline.

LOCATION: remote/hybrid (Northeast USA)

We offer exciting responsibilities:

• Answer unsolicited HCP and patient inquiries with scientifically sound, timely responses
• Own (author) and continuously update standard response documents
• Ensure scientific accuracy and compliant content through MLR review
• Partner with Global Medical Affairs, Legal, Regulatory, and Compliance on early asset development inquiries
• Track inquiry trends and surface insights upstream to feed the GMA insights engine
• Onboard and train the Medical Affairs team using adult learning and assessment best practices.
• Own and maintain the team's knowledge base across obesity, amylin, and petrelintide
• Lead ongoing product and systems training, and serve as a go-to triage resource cross-functionally

Your profile

• You are a scientifically rigorous, detail-oriented communicator who thrives at the intersection of medical information and adult learning. You bring structure to ambiguity, build trusted relationships across GMA, Compliance, Regulatory, Commercial, and the MSL team, and enjoy translating complex science into clear, actionable resources for others.
• PharmD required
• Experience in medical information and/or medical communications within pharma or biotech
• Experience designing and delivering training programs (adult learning and assessment methodology)
• Strong understanding of MLR review processes and compliance requirements in medical communications
• Excellent written and verbal communication skills, with the ability to translate scientific content for varied audiences
• Ability to build cross-functional relationships with Compliance, Regulatory, Commercial, and MSLs

Your new team

You will report to US Medical Affairs, joining our growing US Medical Affairs organization at a pivotal moment as we build out our Boston hub and prepare for the petrelintide launch. Key partners include US Medical Affairs (field medical MSLs and home office team) ,Global Medical Affairs, Compliance, Regulatory, and Commercial.

Let's bond and be bold We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture. Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let's bond and be bold.

We are committed to an inclusive recruitment process and welcome applications from all job applicants.

About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data-driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma-invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Cambridge, Massachusetts. Learn more at www.zealandpharma.com. Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. This expertise has led to an R&D pipeline of innovative investigational candidates designed to address a broad range of disease areas. We have four therapeutic focus areas: obesity, rare diseases, chronic inflammation, and type 1 diabetes. In obesity, our peptide capabilities place us in a unique position to address a vast global health challenge and positively impact hundreds of millions of lives. Within rare diseases, we have a long-standing commitment to deliver new treatments to patients living with congenital hyperinsulinism and short bowel syndrome. For chronic inflammatory diseases, we are progressing peptide programs focused on high-profile targets shown to be difficult to address with small molecules and antibodies. For type 1 diabetes, we aspire to change the management of this disease. Our strategy is to pursue global co-development and commercialization partnerships that complement and extend our capabilities across the value chain to deliver new peptide therapies to people who need them.